Anzeige
+++Bohrstart JETZT angelaufen: American Pacific startet 15.000m-Bohrprogramm: Jagd auf den Tiefen-Jackpot beginnt+++
EQS-News

Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success 15.05.2026, 18:10 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Virtual Science AI Ltd / Key word(s): Product Launch
Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

15.05.2026 / 18:10 CET/CEST
The issuer is solely responsible for the content of this announcement.


LONDON, May 15, 2026 /PRNewswire/ -- Virtual Science AI announces the launch of Medical Competitor AI, an AI solution that analyses competitor medical activity and scientific narratives. The solution – a first in the life sciences industry – is already being used by top pharma companies to drive launch success.

Virtual Science AI Logo
  • First AI-driven competitor asset medical activity and scientific narrative tracking platform
  • Built for launch excellence, new asset and indication peri-launch planning
  • Provides reliable competitor activity data and scientific narrative intelligence

Virtual Science AI's industry-leading medical intelligence platform is used by most of the world's top pharma companies and increasingly by innovative biotech organisations. The medical intelligence system use cases include: integrated medical intelligence, MSL intelligence, AI advisory board intelligence, social intelligence, real-time congress intelligence and now competitor assets intelligence. There is a robust plan for numerous upcoming application releases to address life sciences' most needed intelligence needs.

Competitor asset medical intelligence:

Historically, analysing competitor asset medical activity such as conference coverage, trade activities, social engagement activity, posters, publications and more has been very manual and often not even done.

Life science teams launching new treatments or expanding into new indications need to make plans and select activities, shape and communicate scientific narratives to help bring treatments to the patients who can benefit most.

The competitor intelligence platform provides intel on competitor activities, their narratives and how the community is responding to support with informing where to go with activity and narrative shaping that is unique to the product being launched.

In an environment where budget is increasingly needed to be stretched and headcount in pharma is being reduced, the platform helps teams make smart decisions on where to focus activity and supports narrative building.

Tom Hughes, CEO, Virtual Science AI stated:

"The teams behind the most important launches in pharma have historically had to piece together competitive intelligence manually – or simply go without. Medical competitor AI changes that. It gives launch teams real-time visibility into competitor activity, scientific narratives and community response, so they can make smarter decisions about where to focus and how to shape their story – and ultimately get more patients on the right treatments."

For further information about Virtual Science AI's intelligence solutions, visit: www.virtualscienceai.com.

About Virtual Science AI

Virtual Science AI is world-leading medical intelligence platform company exclusively for life sciences. Providing enterprise-wide advisory panel, integrated medical intelligence, social media intelligence, congress intelligence and competitor intelligence solutions. Virtual Science AI's proprietary medical intelligence platform solutions transform complex scientific data into actionable intelligence, empowering life science teams to drive repeatable value from its AI system enterprise-wide.

Headquartered in London and with operations across Europe, North America, Asia Pacific, and Latin America, Virtual Science AI delivers cutting-edge software as a service (SaaS) solutions for the life-science and healthcare sectors. The company partners with most of the top 20 leading pharmaceutical companies and numerous biotechnology firms.

Logo - https://mma.prnewswire.com/media/2875012/5972973/Virtual_Science_AI_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/virtual-science-ai-launches-first-ai-driven-competitor-activity-tracking-platform-to-support-pharma-asset-launch-success-302773720.html

rt.gif?NewsItemId=EN60823&Transmission_Id=202605151203PR_NEWS_EURO_ND__EN60823&DateId=20260515


15.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2328502  15.05.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer